Journal article
Abstract 198: Lifetime Clinical Benefit of Folic Acid Therapy for Primary Prevention of Stroke in Patients with Hypertension - Projection Based on the CSPPT
Abstract
Background: The CSPPT (China Stroke Primary Prevention Trial) demonstrated a significant risk reduction of first stroke in hypertensive patients treated with EPFA (enalapril plus folic acid) compared to those with enalapril alone, but the life time clinical benefit associated with the use of EPFA is unknown. In this study, we evaluated and quantified the net lifetime clinical benefit of EPFA vs. enalapril alone via assessing stroke-fee life …
Authors
Zhang Z; Zhang T; Lin T; Wang Y; Wang B; Qin X; Xie F; Huo Y; Wang X; Jiang J
Journal
Circulation Cardiovascular Quality and Outcomes, Vol. 12, No. Suppl_1,
Publisher
Wolters Kluwer
Publication Date
April 2019
DOI
10.1161/hcq.12.suppl_1.198
ISSN
1941-7713